BDX
Becton, Dickinson and Company
BDX's fundamentals are mixed: it turned 13% of its revenue into free cash flow, but its operating margin fell 2 points to 9.6%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BDX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Healthy | |
| Under pressure |
BDX's profitability and cash flow are currently healthy, but its revenue and balance sheet are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BDX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $216 | — |
| Cheap | 36x | $119 | -45% |
| Fair | 46x | $152 | -30% |
| Current | 52x | $216 | — |
| Expensive | 62x | $204 | -5.3% |
Historical ranges are pointers, not guarantees.
BDX's PE is 52x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BDX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect BDX's earnings to grow and its profitability to improve, with its revenue holding steady.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BDX Earnings Per Share
BDX and HIMS do not have enough comparable growth data to identify a winner.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5B | -9.5% |
| Q1 2026 | $4.7B | -11% |
| Q4 2025 | $5.3B | +1.6% |
| Q3 2025 | $5.9B | +8.4% |
| Q2 2025 | $5.5B | +10% |
| Q1 2025 | $5.3B | +4.5% |
| Q4 2024 | $5.2B | +9.8% |
| Q3 2024 | $5.4B | +6.9% |
BDX's revenue grew through 2023 and has held roughly level since: $5B last quarter, down 9.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 13% | -2.7 points |
| Q1 2026 | 2% | -8.4 points |
| Q4 2025 | 11% | +1.7 points |
| Q3 2025 | 12% | +0.4 points |
| Q2 2025 | 16% | +4 points |
| Q1 2025 | 10% | -4.2 points |
| Q4 2024 | 8.8% | -0.6 points |
| Q3 2024 | 11% | +4.6 points |
BDX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BDX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
BDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $633M | -39% |
| Q1 2026 | $546M | +1460% |
| Q4 2025 | $549M | -6.6% |
| Q3 2025 | $1B | +14% |
| Q2 2025 | $1B | -6.5% |
| Q1 2025 | $35M | -91% |
| Q4 2024 | $588M | -20% |
| Q3 2024 | $882M | -14% |
BDX's free cash flow has been positive every quarter for seven years: $2.7B over the past year, up 7.1% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BDX on cash flow, with more consistent year-over-year improvement.
BDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -5.5M shares |
| 1 year | -4.2% | -12.1M shares |
| 3 years | -4.4% | -12.8M shares |
| 5 years | -8% | -24M shares |
| Available history | -2.3% | -6.5M shares |
BDX has 275M diluted shares, down 4.2% from a year ago, with $2.5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $2B |
| Q4 2025 | $250M |
| Q3 2025 | $250M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $750M |
| Q3 2024 | — |
BDX spent $2.5B buying back its own shares over the past year, about three times what it spent the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BDX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BDX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 3.7x | Elevated |
| Q1 2026 | 3.5x | Elevated |
| Q4 2025 | 3.7x | Elevated |
| Q3 2025 | 3.7x | Elevated |
| Q2 2025 | 3.8x | Elevated |
| Q1 2025 | 4.1x | High |
| Q4 2024 | 3.8x | Elevated |
| Q3 2024 | 3.9x | Elevated |
BDX's net debt is about 3.7 years of its operating earnings (EBITDA), about the same as a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over BDX on leverage, with a lower net debt burden relative to earnings.
BDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.7 | Overbought |
| Stochastic | 95.0 | Overbought |
BDX's weekly RSI is 74 (overbought) and its Stochastic is 95 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BDX PE vs Healthcare Sector
| Metric | BDX | Sector median | Relative |
|---|---|---|---|
| PE | 52x | 26x | 102% above |
| PE % | 74 | 29 | 45 pts above |
BDX is trading at 52x earnings, a 102% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $195.1 | 11% above |
| 20 week MA | $181.8 | 19% above |
| 50 week MA | $166.8 | 29% above |
| 100 week MA | $161.5 | 34% above |
| 200 week MA | $176.9 | 22% above |
BDX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $209.3 | $190.2 | -9.1% |
| 2021 | $190.2 | $190.9 | +0.4% |
| 2022 | $190.9 | $200.1 | +4.8% |
| 2023 | $200.1 | $191.7 | -4.2% |
| 2024 | $191.7 | $179.6 | -6.3% |
| 2025 | $179.6 | $154.4 | -14% |
| 2026 YTD | $154.4 | $215.7 | +40% |
BDX has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.